Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 30, 2015
Pharmacy Choice - News - Pharmaceutical Development - January 30, 2015

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

1/30/15 - Amgen Files Applications in the US and Europe for Kyprolis (carfilzomib) for the Treatment of Relapsed Multiple Myeloma [Professional Services Close - Up]
Amgen and its subsidiary Onyx Pharmaceuticals reported the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency for Kyprolis for Injection to seek approval for the treatment of patients with relapsed multiple myeloma who have received at
1/30/15 - Data from Veterans Affairs Medical Center Provide New Insights into Abdominal Aortic Aneurysm (Costs of repair of abdominal aortic aneurysm with...
By a News Reporter-Staff News Editor at Insurance Weekly News Investigators publish new report on Cardiovascular Diseases and Conditions. Our news journalists obtained a quote from the research from Veterans Affairs Medical Center, "Within each selected system, EVR costs are compared with open repair costs. Health care utilization data were obtai
1/30/15 - Dr. Jeffrey H. Lawson to Keynote at the International Symposium for Endovascular Therapy [Professional Services Close - Up]
Jeffrey H. Lawson, M.D., Ph.D., Vice Chair for Research, Professor of Surgery and Pathology at Duke University Medical Center, Director of the Vascular Research Laboratory, Director of Clinical Trials for the Department of Surgery and clinical consultant to Humacyte, is the keynote speaker at the 27th International Symposium on Endovascular Therapy
1/30/15 - Johnson & Johnson: U.S. FDA Approves IMBRUVICA (ibrutinib) for the Treatment of Waldenstrom's Macroglobulinemia: First FDA-Approved Therapy for This Disease
Release date- 29012015- HORSHAM, PA- Janssen Biotech, Inc. today announced that the U.S. Food and Drug Administration has approved IMBRUVICA capsules as the first therapy indicated specifically for patients with Waldenstrom's macroglobulinemia, 1 a rare, indolent type of B-cell lymphoma. IMBRUVICA was granted Breakthrough Therapy Designation for WM
1/30/15 - Octapharma USA Gets FDA Approval for 2nd Octagam 10 Percent Manufacturing Site [Professional Services Close - Up]
Octagam 10 percent for the U.S. market can now be manufactured at FDA- licensed facilities in both Stockholm, Sweden and Vienna. "The FDA approval of Octapharma's Vienna manufacturing site for Octagam 10 percent is great news for patients, as it will help facilitate product availability and enhances production flexibility," said Flemming Nielsen,
1/30/15 - Reports Summarize Nephrology Study Results from Toranomon General Hospital (Effects of topiroxostat on the serum urate levels and urinary albumin...
Reports Summarize Nephrology Study Results from Toranomon General Hospital. According to news originating from Tokyo, Japan, by NewsRx correspondents, research stated, "Topiroxostat, a selective xanthine oxidase inhibitor, shows effective reduction in the serum urate level in hyperuricemic patients with or without gout. Our news journalists obtaine
1/30/15 - St. Jude Medical Updates on FDA Approval of FlexAbility Ablation Catheter [Health & Beauty Close - Up]
St. Jude Medical reported U.S. Food and Drug Administration approval of the FlexAbility Ablation Catheter, a new ablation technology used by electrophysiologists for the treatment of cardiac arrhythmias. Andrea Natale, executive medical director at the Texas Cardiac Arrhythmia Institute. "As we developed the FlexAbility ablation catheter, we worke
1/30/15 - Stifel Nicolaus Boosts Array Biopharma Price Target to $9.00 (ARRY) [Cihan News Agency (Turkey)]
Array Biopharma had its price objective raised by Stifel Nicolaus from $6.00 to $9.00 in a research report released on Monday morning. Analysts at Zacks downgraded shares of Array Biopharma from an outperform rating to a neutral rating and set a $5.20 price target on the stock in a research note on Tuesday, January 6th. Separately, analysts at Jeff
1/30/15 - Studies from University of Trondheim Hospital Further Understanding of Hallux Valgus (Prospective Randomized Study of Chevron Osteotomy Versus...
Studies from University of Trondheim Hospital Further Understanding of Hallux Valgus. By a News Reporter-Staff News Editor at Energy Weekly News Researchers detail new data in Musculoskeletal Diseases and Conditions. According to news reporting originating in Trondheim, Norway, by VerticalNews editors, the research stated, "We conducted a prospec
1/30/15 - Sweden,United States : FDA approves new strength of Norditropin FlexPro [TendersInfo (India)]
Novo Nordisk declared that the Food and Drug Administration has given green signal to a new 30 mg/3. 0 mL strength of Norditropin FlexPro pen. Norditropin FlexPro is indicated for growth failure in children due to inadequate endogenous GH secretion, children with short stature associated with Noonan or Turner syndrome, children with short stature b
1/30/15 - Symplmed Gets FDA Approval of Prestalia [Professional Services Close - Up]
Symplmed Pharmaceuticals reported that the U.S. Food and Drug Administration has approved Prestalia tablets, licensed from Servier, for the treatment of hypertension. "This is a significant milestone for Symplmed and for our development partner Servier as it is the first product from our perindopril pipeline to receive FDA approval," said Erik Eme
1/30/15 - SynteractHCR to Present at International and Domestic Clinical Trials Conferences [Manufacturing Close - Up]
SynteractHCR will participate in two biopharmaceutical and life science conferences in early February: the European CRO Federation's 2nd European Conference on Clinical Research in Paris, and the 7th Annual Outsourcing in Clinical Trials West Coast Conference in San Francisco. Martine Dehlinger-Kremer, is attending EUCROF's conference and chairing
1/30/15 - Theravectys Secures Grant from Bpifrance [Professional Services Close - Up]
Theravectys reported the grant of EUR1.9 million from Bpifrance in the form of a repayable advance as part of the Development of Innovation Assistance program. With this support, Theravectys will be able to accelerate the optimization of its manufacturing process and the production of lentiviral vectors and T-cell therapies to be used in clinical t
1/30/15 - United States : USFDA calls off approval for Ranbaxy s capsules [TendersInfo (India)]
The U.S. Food and Drug Administration has called off Ranbaxy Laboratories s 180- day exclusivity to market esomeprazole magnesium delayed release capsule 20 mg and 40 mg in the U.S. Ranbaxy commented On November 4, 2014, we received a notice from the US FDA rescinding our tentative approvals for esomeprazole magnesium delayed release capsule 20 mg
1/29/15 - Actinium Files Pre-IND Meeting Request to FDA for Iomab-B Drug Candidate [Health & Beauty Close - Up]
Actinium Pharmaceuticals has submitted a request for a pre-IND meeting to the U.S. Food and Drug Administration for the company's Iomab-B drug candidate currently undergoing final preparations to start the pivotal Phase 3 trial in mid-2015. stated Kaushik J. Dave, President and Chief Executive Officer of Actinium Pharmaceuticals "We believe that ou
1/29/15 - AgeneBio secures ADDF grant for new approach to delaying onset of Alzheimer's Dementia [EMBIN (Emerging Markets Business Information News]
AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling amnestic mild cognitive impairment, the pre-dementia stage of Alzheimer's disease, and other neurological and psychiatric diseases, announced that the company has received a $900,000 grant from the Alzheimer's Drug Discovery Foundation.
1/29/15 - AliveCor Announces FDA Clearance for Two New Automated Detectors for Normal Recordings and Noise Interference
AliveCor, Inc. announced today that the U.S. Food and Drug Administration has granted the company clearance for two new algorithms giving users instant feedback on their electrocardiogram recordings and expanding its automated interpretation service offerings. AliveCor's new analysis processes include a Normal Detector that identifies when no...
1/29/15 - Aquinox Pharmaceuticals to Present at Upcoming Investor Conferences
Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox's President& CEO, will present a corporate overview at two upcoming investor conferences. 2015 Leerink Global Healthcare Conference..
1/29/15 - Array Biopharma PT Raised to $9.00 at Stifel Nicolaus (ARRY) [Jerusalem Post (Israel)]
Research analysts at Stifel Nicolaus boosted their target price on shares of Array Biopharma from $6.00 to $9.00 in a report released on Monday. Analysts at Zacks downgraded shares of Array Biopharma from an outperform rating to a neutral rating and set a $5.20 price target on the stock in a research note on Tuesday, January 6th. Separa
1/29/15 - Bellerophon Therapeutics Strengthens Drug and Device Development Capabilities with Key Management Additions
Debbie's significant experience leading the pulmonary arterial hypertension program for Novartis Pharmaceuticals AG, combined with her tenures as a physician at Massachusetts General Hospital and Harvard Medical School, where she focused on pulmonary and critical care medicine, make her a natural choice as the medical lead of our INOpulse programs.
1/29/15 - BioRestorative Therapies Reports Successful Meeting with FDA
By a News Reporter-Staff News Editor at Gene Therapy Weekly BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based products and therapies for various personal medical applications, announced that it has had a successful pre-investigational new drug meeting with the U.S. Food and Drug Administration concerning its
1/29/15 - Cellceutix Released Results of Phase 2b Clinical Trial of Brilacidin [Professional Services Close - Up]
Cellceutix Corp. reported that results of its recently completed phase 2 b clinical trial "A Randomized, Double-Blind Study Comparing Single-Dose and Short-Course Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin& Skin Structure Infections" will be given in an oral presentation at the European Congress of Clinical Microbiology and..
1/29/15 - COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society's 97th Annual Meeting & Expo
January 29, 2015 Radnor, Penn., U.S. and Gteborg, Sweden Cortendo AB [ticker: CORT on NOTC-A], a global biopharmaceutical company initially focused on orphan endocrine disorders, today announced that it will present the study protocol of its global Phase 3 study of COR-003 in patients with endogenous Cushing's syndrome at ENDO 2015: The E
1/29/15 - Corcept Therapeutics Announces Fourth Quarter and Full Year 2014 Revenue, Provides 2015 Revenue Guidance and Clinical Update
Fourth quarter 2014 revenue grows to $9.0 million, a 24 percent increase from the prior quarter and a 119 percent increase from the same period last year Full year 2014 revenue of $26.6 million exceeds 2013 results by 156 percent 2015 revenue guidance is $47-53 million Dose-finding study completed; efficacy study beginning in Phase 1/ 2 trial of Ko
1/29/15 - Cortendo AB: COR-003 Phase 3 Study Protocol to Be Presented at ENDO 2015: The Endocrine Society's 97th Annual Meeting & Expo
RADNOR, Pa.& STOCKHOLM Regulatory News:. Cortendo AB, a global biopharmaceutical company initially focused on orphan endocrine disorders, today announced that it will present the study protocol of its global Phase 3 study of COR-003 in patients with endogenous Cushing s syndrome at ENDO 2015: The Endocrine Society s 97th Annual Meeting& E
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Drug Therapy Management Series Part I: Cardiovascular Disorders
This lesson is supported by:
RxSchool
Workplace Safety & Joint Commission Standards for Pharmacy Professionals
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415